Status:
COMPLETED
Clinical Study to Assess Safety, PK and PD Parameters of CDR132L
Lead Sponsor:
Cardior Pharmaceuticals GmbH
Conditions:
Heart Failure
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety, pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart failure of ischemic ori...
Detailed Description
Objectives: Primary • To assess the safety of one single and one repeated dose of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1-3). Secondary • To characterize the pharma...
Eligibility Criteria
Inclusion
- Stable heart failure of ischemic origin
Exclusion
- Heart failure of non-ischemic origin (hypertensive heart disease, myocarditis, alcoholic cardiomyopathy and cardiac dysfunction due to rapid atrial fibrillation),
Key Trial Info
Start Date :
June 21 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 26 2020
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04045405
Start Date
June 21 2019
End Date
June 26 2020
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge
London, United Kingdom, SE1 1YR